We found that the proportion of men with aggressive prostate cancer who carried a BRCA2 pathogenic variant exceeded that observed in men with non-aggressive prostate cancer (18/787 carriers, 2.3% and 4/769 carriers, 0.5%, respectively; p = 0.004). This evidence concerns the gene BRCA2 and prostate carcinoma.